NTLA-5001 is Intellia’s first ex vivo candidate using its proprietary cell engineering process for the treatment of cancer to enter clinical study
NTLA-5001 targets Wilms’ Tumor 1 (WT1), an overexpressed intracellular antigen on many hematologic malignancies and solid tumors
Initiation of patient screening in Phase 1/2a study of NTLA-5001 expected by year-end
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.